Despite Marinus’s best efforts there is no disguising the disappointment at the performance of oral ganaxolone in the group’s postpartum depression study Magnolia. While the company attempted a quick pivot back to the project’s IV form, and touted additional future ganaxolone uses, its stock crashed 60% this morning.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,